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Aims: Dual platelet inhibition using anti-P2Y12 drugs and aspirin is the standard of care
in patients after percutaneous coronary interventions (PCI). Prasugrel and ticagrelor have
been shown to be more potent than clopidogrel with less high on-treatment platelet
reactivity. Whether differences in long-term adherence to these drugs can partly explain
different antiplatelet efficacy has not been studied so far. The objective was to compare
the long-term P2Y12 receptor inhibition and drug adherence to different anti-P2Y12
drugs, and to assess the impact of adherence on the pharmacodynamic effect.
Methods: Monocentric, prospective, observational study. Stable outpatients treated
with clopidogrel 75 mg once daily, prasugrel 10 mg once daily or ticagrelor 90 mg twice
daily after PCI with stent implantation were included. Drug adherence was recorded
during 6 months using electronic monitoring. Platelet responsiveness was assessed
with the vasodilator-stimulated phosphoprotein platelet reactivity index (VASP-PRI) at
inclusion, 3 and 6 months.
Results: 120 patients had VASP-PRI and adherence data available. At 6-months, mean
VASP-PRI (±SD) was 17.7 ± 11.0% with ticagrelor, 29.2 ± 15.5% with prasugrel and
47.2 ± 17.6% with clopidogrel (ANOVA, P < 0.0001).
Median [IQR] taking adherence was 96 [82–100]% with ticagrelor, 100 [97–101]% with
prasugrel and 100 [99–101]% with clopidogrel (p= 0.0001). Median [IQR] correct dosing
was 88 [73–95]% with ticagrelor, 97 [92.5–98]% with prasugrel and 98 [96–99]% with
clopidogrel (p = 0.0001).
Anti-P2Y12 drug (p ≤ 0.001) and diabetes (p = 0.014) emerged as predictors of poor
antiplatelet response after adjusting for age, BMI, sex, and CYP2C19∗2 carriers status.
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Conclusion: Drug adherence to anti-P2Y12 drugs assessed with electronic monitoring
was very high. However, anti-P2Y12 drugs showed significant differences in antiplatelet
activity, with newer anti-P2Y12 drugs ticagrelor and prasugrel exerting a stronger P2Y12
receptor inhibition.
These data suggest that pharmacokinetic-pharmacodynamic differences between
oral anti-P2Y12 drugs are more important than adherence in determining antiplatelet
efficacy when adherence to prescription is high.
The study was registered (Current Controlled Trials ISRCTN85949729).
Keywords: anti-P2Y12 drugs, VASP-PRI, elective coronary stenting, drug adherence, MEMS R©, percutaneous
coronary angioplasty intervention
INTRODUCTION
Dual antiplatelet therapy (DAPT) with aspirin and an oral anti-
P2Y12 drug targeting the ADP-induced platelet activation is
the recommended standard of care for secondary prevention
after elective percutaneous coronary interventions (PCI) (Silber
et al., 2005; Levine et al., 2011). Within the acute phase
(1 month) after stent implantation, the main concern is early
stent thrombosis due to DAPT interruption/non-adherence
(Naidu et al., 2012). Recently non-adherence to DAPT in the
subacute phase (1–6 months) of PCI with second generation drug
eluted stents (DES) implantation has been correlated with the
occurrence of thrombotic outcomes at 1 year (Cutlip et al., 2015).
Clopidogrel has been the oral anti-P2Y12 drug of choice
for years, but has shown significant limitations, due to its
pharmacokinetic and pharmacodynamic characteristics. It is
a prodrug requiring transformation in the liver resulting in
unpredictable and delayed onset of action, has modest, variable
and irreversible antiplatelet efficacy, its action is influenced
by several demographic and genetic determinants. (Hochholzer
et al., 2010) The new anti-2Y12 drugs, prasugrel (Jernberg et al.,
2006; Wiviott et al., 2007) and ticagrelor (Wallentin et al.,
2008, 2009) have been shown to have more predictable and
greater antiplatelet efficacy than clopidogrel. Nevertheless, the
short plasma half-life of 7–8.5 h of ticagrelor mandate its twice
daily dosing (b.i.d.) (Butler and Teng, 2010), which may lead
to slightly more missed doses compared to the once daily (o.d.)
regimen of clopidogrel and prasugrel (Comte et al., 2007). To our
knowledge, data comparing the impact of adherence on the long-
term (6–12 months after PCI) antiplatelet efficacy of different
anti-P2Y12 drugs are not available so far.
The main objective of this study was therefore to compare the
long-term anti-P2Y12 receptor inhibition and drug adherence
profile of the three anti-P2Y12 drugs after elective PCI, and
to investigate the impact of drug adherence on the long-term
platelet inhibition.
MATERIALS AND METHODS
Study Population and Design
We screened all consecutive adult patients admitted to the
cardiology interventional unit of the Lausanne University
Hospital for elective PCI from April 2010 through January
2014. Patients were enrolled if they had undergone PCI with
implantation of at least one stent and had been prescribed
maintenance treatment with an anti-P2Y12 drug (clopidogrel
75 mg o.d. or prasugrel 10 mg o.d. or ticagrelor 180 mg b.i.d.)
for at least 6 months. The main exclusion criteria were: non-ST-
segment elevation myocardial infarction or ST-segment elevation
within 30 days prior to inclusion.
Eligible patients were randomly assigned (block size 1:2)
to a follow-up without or with anti-P2Y12 drug adherence
monitoring using the Medication Event Monitoring System
(MEMS R©).
For this observational analysis, we only selected patients of
the active arm of the trial. These patients all had electronic
monitoring of their anti-P2Y12 drug intake.
The vasodilator-stimulated-phosphoprotein (VASP) platelet-
reactivity-index (PRI) was measured at inclusion, 3 and 6 months
as marker of P2Y12 receptor antagonists’ efficacy. The primary
endpoint of the study was the VASP-PRI at 6 months.
All patients gave their written informed consent. The study
was approved by the local Ethics Committee of the University of
Lausanne, Switzerland, and was carried out in accordance of the
principles of the Declaration of Helsinki. The study was registered
(Current Controlled Trials ISRCTN85949729).
Study Procedures
Platelet Function Assay and Evaluation of Anti-P2Y12
Drug Efficacy
Platelets activity was assessed with citrated whole blood using the
Platelet VASP/P2Y12 assay (VASP-assay, Platelet VASP/P2Y12,
Biocytex, Marseille, France), a flow cytometry assay that
specifically assesses the antiplatelet efficacy of anti-P2Y12 drugs
as described previously (Aleil et al., 2005; Forni Ogna et al.,
2016). Results are expressed in terms of platelet reactivity index
(PRI). Poor response to the anti-P2Y12 drug (high on-treatment
platelet response, HPR) was defined as a VASP-PRI ≥ 50%. This
value has been shown to be the optimal cut-off to exclude major
cardiovascular events after PCI (Tantry et al., 2013).
Genotyping
Genomic DNA was extracted from EDTA blood samples
with the FlexiGene DNA extraction kit (QIAGEN, Basel,
Switzerland). The following single nucleotide polymorphism
(SNPs) were detected by real-time PCR with 5′-nuclease allelic
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FIGURE 1 | Flow diagram of the study.
discrimination assays (ABI PRISM 7000; Applied Biosystems,
Luzern, Switzerland) (Jaquenoud Sirot et al., 2009): CYP2C19∗2,
CYP2C19∗3, CYP2C19∗17. Patients were classified into 6
predicted phenotypes: carriers of two functional (∗1) alleles
(∗1/∗1; extensive metabolizers), carriers of 1 functional allele and
1 non-functional (∗2) alleles (∗1/∗2; intermediate metabolizers),
carriers of 1 gain-of-function allele (∗17) and 1 non-functional
allele (∗17/∗2; intermediate metabolizers), carriers of only non-
functional allele (∗2/∗2; poor metabolizers), carriers of only gain
of function allele (∗17/∗17; rapid metabolizers) and carriers
of 1 functional and 1 gain of function allele (∗1/∗17; rapid
metabolizers). Subjects were also dichotomously classified as
“carriers” of at least 1 non-functional allele (∗1/∗2∗, ∗17/∗2, and
∗2/∗2) and “non-carriers” (∗1/∗1, ∗1/∗17, and ∗17/∗17).
Adherence Monitoring
Adherence monitoring: medication adherence is the process by
which patients take their medication as prescribed. It is composed
of three elements: (1) initiation of therapy, (2) implementation
of the dosing regimen, and, eventually, (3) discontinuation
of therapy. In this study, all patients initiated therapy and
dosing history data were censored at treatment discontinuation.
Therefore, the adherence focus is the implementation of the
dosing regimens. The Medication Event Monitoring System –
MEMS R© was used to automatically compile medication dosing
history data during the 6-months study period. This system
entails the use of a tablet bottle closure that electronically records
the time and date when the cap is removed. The data are
collected, recorded and can be processed to generate a graphic
representation of the dates and times of bottle openings.
Adherence data summarize daily implementation of the
dosing regimens using two different summary statistics: (Wessels
et al., 2012)
(1) Taking adherence (Tac): the proportion of prescribed drug
taken during the time window, calculated as:
N◦ of openings/N◦ of prescribed doses× 100.
The Tac measure reflects both the average dose received
over a given period and the total dose received over that
period. However, it fails to distinguish between a patient
who takes his medication regularly and a patient who
balances periods of underdosing with periods of overdosing
and it captures no information about the precise timing of
drug intake.
(2) Correct dosing (Cod): the percentage of days with correct
number of doses taken, calculated as:
Number of days with N◦ of openings as prescribed/N◦ of
monitored days× 100.
The Cod measure captures some measure of the closeness
to ‘correct adherence.’ It reflects the degree of regularity in
lifestyle.
In the adherence summary, we did not consider periods
without drug intake because of medical prescription (for
example after a bleeding episode).
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Safety
Bleeding complications were characterized according to the
GUSTO (Global Utilization of Streptokinase and Tpa for
Occluded Arteries) definition for bleeding (Mehran et al., 2011).
Statistical Analysis
The VASP-PRI results were compared between groups using
ANOVA; adherence results were compared between groups using
the Kruskal–Wallis test.
Linear mixed-effects models were used to model longitudinal
VASP-PRI and HPR data.
The analyses of the determinants of poor response to the anti-
P2Y12 drug were performed in all treatment groups: The analyses
of VASP-PRI determinants was performed in all treatment
groups: in a logistic regressions for models adjusting for other
covariates, we included the measures of HPR at 6 months as
dependent variables and anti-P2Y12 drug treatment group, age,
sex and CYP2C19∗2 carriers status as covariates. The analyses
TABLE 1 | Demographic, clinical and procedural characteristics of the study patients according to the anti-P2Y12 drug at inclusion.
Clopidogrel (n = 75) Prasugrel (n = 24) Ticagrelor (n = 30) p
Demographics
• Race (Caucasian) 74 (98.7) 24 (100.0) 30 (100.0) 0.701
• Age, years 65.3 ± 10.4 57.5 ± 10.8 59.4 ± 10.4 0.002
• Sex (Male) 62 (82.7) 21 (87.5) 27 (90.0) 0.602
• BMI, kg/m2 27.6 ± 3.5 29.0 ± 4.7 26.5 ± 2.9 0.048
Cardiovascular risks factors
• Diabetes 15 (20) 5 (20.8) 6 (20.0) 0.996
• Hypertension 59 (78.7) 16 (66.7) 17 (56.7) 0.068
• Dyslipidemia 68 (90.7) 20 (83.3) 23 (76.7) 0.162
• Smoker (current or former) 49 (65.3) 18 (75.0) 21 (70.0) 0.662
Indication to revascularization
• Stable angina 24 (32) 3 (12.5) 3 (10.0) 0.021
• Unstable angina 14 (18.7) 5 (20.8) 2 (6.7) 0.262
• Positive functional test 13 (17.3) 1 (4.2) 1 (3.3) 0.059
• Elective stent post ACS 30 (40) 15 (62.5) 24 (80.0) 0.001
• Drug eluted stents 1.4 ± 0.7 1.3 ± 0.5 1.7 ± 1.3 0.143
Prior cardiac history
• ACS 39 (52.0) 18 (75.0) 24 (80.0) 0.010
• Coronary artery bypass graft 11 (14.7) 3 (12.5) 1 (3.3) 0.264
• PCI without stent 11 (14.7) 1 (4.2) 0 (0) 0.041
• PCI with stent 38 (50.7) 17 (70.8) 23 (76.7) 0.024
Values are expressed as means ± SD or n with percentages between brackets. ACS, acute coronary syndrome; BMI, body mass index; eGFR ckd-epi, estimated
glomerular function rate - chronic kidney disease epidemiology collaboration; PCI, percutaneous coronarography intervention.
TABLE 2 | Pharmacotherapy, biological results and genotyping of the study patients according to the anti-P2Y12 drug at inclusion.
Clopidogrel (n = 75) Prasugrel (n = 24) Ticagrelor (n = 30) p
Pharmacotherapy
• Aspirin 74 (98.7) 24 (100.0) 30 (100.0) 0.701
• Beta-blocker 54 (72.0) 21 (87.5) 27 (90.0) 0.066
• RAAS -inhibitor 63 (84.0) 21 (87.5) 24 (80.0) 0.760
• Calcium channel blocker 7 (9.3) 1 (4.2) 4 (13.3) 0.521
• Diuretic 14 (18.7) 3 (12.5) 4 (13.3) 0.691
• Statin 71 (94.7) 23 (95.8) 29 (96.7) 0.903
Laboratory results
• Serum creatinine, µmol/l 89.5 ± 20.8 89.1 ± 12.6 82.3 ± 8.5 0.159
• eGFR ckd-epi, ml/min/1.73 m2 77.0 ± 17.1 81.2 ± 16.7 86.9 ± 12.6 0.019
• Total cholesterol, mmol/l 4.2 ± 1.0 4.1 ± 0.7 4.0 ± 0.7 0.548
• LDL-cholesterol, mmol/l 2.3 ± 0.7 2.2 ± 0.5 2.0 ± 0.6 0.286
• HDL-cholesterol, mmol/l 1.3 ± 0.4 1.2 ± 0.3 1.2 ± 0.3 0.428
• Fasting glucose, mmol/l 6.2 ± 1.6 6.2 ± 1.1 5.8 ± 0.8 0.399
• Hemoglobin, g/l 143.1 ± 11.7 148.8 ± 11.6 148.3 ± 11.5 0.035
Genotyping
• CYP2C19∗2 allele carriers 20 (26.7) 6 (25.0) 10 (33.3) 0.747
Values are expressed as means ± SD or n with percentages between brackets. RAAS, renin-angiotensin-aldosterone-system.
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FIGURE 2 | Boxplot of VASP-PRI results over time according to the anti-P2Y12 drug. VASP-PRI, vasodilator-stimulated-phosphoprotein-phosphorylation-platelet-
reactivity-index.
were performed using STATA 14.0 (Stata Corp, College Station,
TX, United States). P < 0.05 was considered as statistically
significant.
RESULTS
From April 2010 through January 2014, a total of 822 patients
were screened and 191 recruited and randomized in two
groups, with and without drug adherence monitoring. Only
the 129 patients having their adherence of anti-P2Y12 drug
monitored using the Medication Event Monitoring System
(MEMS R©) were included in this analysis. Supplementary Table 1
shows the demographic characteristics of included and not
included patients, who only slightly differed in the “Indication to
revascularisation” item.
Of the 129 patients included, 75 were treated with clopidogrel,
24 with prasugrel and 30 with ticagrelor. Figure 1 shows the flow-
chart of the study. Tables 1, 2 show the demographic, clinical and
biological characteristics of the patients at inclusion, according
to the ongoing anti-P2Y12 drug. Patients with clopidogrel
treatment were older, had a lower glomerular filtration rate,
and had less frequently a positive history of acute coronary
syndrome or of PCI with stent implantation before the last
procedure.
VASP-PRI Results, HPR and Predictors
of the On-treatment Anti-P2Y12 Drug
Response
VASP-PRI values at inclusion, 3 and 6 months for each anti-
P2Y12 drug are shown in Figure 2.
VASP-PRI at inclusion and 6-month was lowest in ticagrelor
treated patients. Mean ± SD VASP-PRI at inclusion was
18.6 ± 8.5% with ticagrelor, 26.4 ± 12.7% with prasugrel and
47.6 ± 18.4% with clopidogrel (ANOVA p < 0.0001). VASP-PRI
at 6-month was 17.7 ± 11.0% with ticagrelor, 29.2 ± 15.5% with
prasugrel and 47.2± 17.6 % with clopidogrel (p< 0.0001).
Six-months efficacy was superior both when comparing
ticagrelor to clopidogrel (p < 0.0001) and ticagrelor to prasugrel
(p = 0.0046). We observed large between-patient variability at
each visit and in the three treatment groups. Nevertheless, overall
mean VASP-PRI values remained stable over the 6-months period
in the three groups (p = 0.691 for ticagrelor, p = 0.849 for
clopidogrel, p = 0.525 for prasugrel). The proportion of HPR
at inclusion was 0% with ticagrelor and prasugrel, vs.45.3% with
clopidogrel (p < 0.0001); at 6 months, this proportion was 0%
with ticagrelor, 12.5% with prasugrel and 49.3% with clopidogrel
(p< 0.0001).
When applying linear mixed-effects models to model
longitudinal VASP-PRI data, significant differences between
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FIGURE 3 | Taking adherence (upper) and correct adherence (lower) over the 6-months monitoring period according to the anti-P2Y12 drug. Correct
adherence (Cod), proportion of days with correct dosing during the time window; Taking adherence (Tac), proportion of prescribed drug taken during the time
window.
treatment groups were confirmed (P ≤ 0.001 for absolute VASP-
PRI values, P ≤ 0.001 for HPR). No significant effect of time was
observed (P = 0.309 for absolute VASP-PRI values, P = 0.140 for
HPR) at 6 months.
Anti-P2Y12 drugs (p ≤ 0.001) and diabetes (p = 0.014)
emerged as predictors of poor antiplatelet response after
adjusting for age, sex, BMI, and CYP2C19∗2 carriers
status.
CYP2C19∗2 carriers status was associated with HPR
only in patients treated with clopidogrel (p = 0.0083 with
clopidogrel; p = 0.0678 with prasugrel; p = 0.2931 with
ticagrelor).
Results of Adherence Summary
Statistics
Figure 3 shows the monthly adherence summary statistics over
the 6-months of monitoring according to the P2Y12 receptor
antagonist treatment group.
Adherence statistics were lowest in ticagrelor vs. clopidogrel
and prasugrel treated patients: median [IQR] taking adherence
(Tac) was 96 [82–100]% with ticagrelor, 100 [99–101]% with
clopidogrel and 100 [97–101]% with prasugrel (p = 0.0001);
median [IQR] correct dosing (Cod) was 88 [73–95]% with
ticagrelor, 98 [96–99]% with clopidogrel and 97 [92.5–98]% with
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FIGURE 4 | Association between VASP-PRI at 6-months and taking
adherence (upper) and correct adherence (lower) in the 30 days preceding
the VASP-PRI assay. VASP-PRI, vasodilator-stimulated-phosphoprotein-
phosphorylation-platelet-reactivity-index.
prasugrel (p = 0.0001). Figure 4 shows the 6-month VASP-PRI
results in the three anti-P2Y12 drugs according to the Tac and
Cod during the month before VASP-PRI assessment.
Results of Safety
Table 3 reports all adverse events occurring during the 6-months
study period. Specifically, we did not observe a higher incidence
of bleeding episodes under prasugrel and ticagrelor, despite their
more powerful platelets inhibition.
Three patients had to stop the trial prematurely: one
clopidogrel treated patient in the context of recurrent vesical
bleeding, one ticagrelor treated patient had to been switched
to an alternative PY12 receptor inhibitor because of nausea
and headache, in a third case ticagrelor was stopped by the
treating physician because of fear of interactions with other
drugs.
We did not observe any between-treatment groups difference
in the incidence of other adverse events (data not shown).
DISCUSSION
The main finding of this study is that despite a slightly lower
adherence to ticagrelor, P2Y12 inhibition is strongest with this
drug after 6 months of treatment compared to prasugrel and
clopidogrel.
To our knowledge, this is the first study assessing the
impact of long-term (6–12 months) adherence on P2Y12
receptor inhibition. The clinical impact of antiplatelet drugs
discontinuation after PCI with DES implantation in the subacute
phase (>1 month) after stent implantation is controversial. First
generation DES has increased the risk for stent thrombosis
beyond the traditional subacute (first month) period as compared
with bare-metal stents (Daemen et al., 2007). Non-adherence
to duals antiplatelet therapy (DAPT) in patients treated with
DES, defined as missing ≥1 days of either medication within
the first 6 months, has been independently associated with
adverse thrombotic outcomes at 1 year. In contrast, non-
adherence after 6 months has not been associated with
increased subsequent risk for the composite endpoint of
death or myocardial infarct, if the patient had been fully
adherent to DAPT during the first 6 months (Cutlip et al.,
2015).
These data are in contrast to several studies reporting no
adverse impact of DAPT discontinuation after the first month
(Ferreira-Gonzalez et al., 2012; Naidu et al., 2012; Silber et al.,
2014).
Taking adherence results – the proportion of prescribed drug
taken during the time window, reflecting both the average dose
received over a given period and the total dose received over that
period -, were excellent and stable over the 6-months monitored
period in the three treatment groups; ticagrelor treated patients
showed a slightly lower taking adherence.
When refining the analysis, the percentage of days with drug
taken as prescribed was significantly lower in patients treated
with ticagrelor b.i.d. compared to o.d.
When analyzing the drug dosing histories of 5014 patients
extracted from an electronically compiled dosing history
database, Vrijens et al. (2014) showed a higher likelihood of
missing a dose in patients on b.i.d. ticagrelor regimen with
respect to o.d. clopidogrel. Their main finding was that although
patients treated twice daily more frequently missed single dose
compared with patients treated once daily, the calculated level
of platelet inhibition remained higher for ticagrelor twice daily
compared with clopidogrel once daily. They underlined the need
to shift focus from percentages of prescribed doses taken to
pharmacometrically equivalent dosing errors, which should be
better suited to predict therapeutic consequences of missed doses.
In analogy with the above mentioned study findings, we
showed no meaningful pharmacodynamic impact of these
execution irregularities on the ticagrelor-induced platelets
inhibition.
The lack of therapeutic consequences of drug intake
irregularities on medicament efficacy is highlighted by
Figure 5, which show the dosing history of two patients
on ticagrelor b.i.d. The electronically compiled drug dosing
history data reveal major differences in the dynamics over
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TABLE 3 | Adverse events at 6 months.
Total (n = 129) Clopidogrel (n = 75) Prasugrel (n = 24) Ticagrelor (n = 30) P-value
Ischemic events, N (%) 4 (3.2) 2 (2.7) 1 (4.2) 1 (3.9) 0.598
• Unstable angina 3 (2.4) 2 (2.7) 1 (4.2) 0 (0) 0.462
• ACS 0 (0) 0 (0) 0 (0) 0 (0)
• Stent thrombosis 1 (0.8) 0 0 1 (3.9) 0.152
Coronary interventions, N (%) 14 (10.9) 7 (9.3) 5 (21.7) 2 (7.7) 0.274
• Angioplasty 12 (9.7) 5 (6.7) 5 (21.7) 2 (7.7) 0.197
Bleeding (GUSTO criteria), N (%) 67 (65.9) 38 (50.7) 19 (79.2) 19 (93.3) 0.102
• Severe or Life-threating 0 (0) 0 (0) 0 (0) 0 (0)
• Moderate 0 (0) 0 (0) 0 (0) 0 (0)
• Mild 67 (65.9) 38 (50.7) 19 (79.2) 19 (93.3) 0.10
Values are expressed as percentages between brackets. ACS, acute coronary syndrome; GUSTO (Global Utilization Of Streptokinase And Tpa For Occluded
Arteries) definition for bleeding: Severe or Life-threatening (intracerebral hemorrhage or bleeding resulting in substantial hemodynamic compromise requiring treatment),
Moderate (requiring blood transfusion but not resulting in hemodynamic compromise), Mild (bleeding that does not meet above criteria).
FIGURE 5 | Dosing chronology plot used to visualize the dosing history of two
patients on ticagrelor b.i.d [Patient 1 (upper), Patient 2 (lower)]. Dosing
chronology plot of two participants. The horizontal axis displays the days
since the inclusion visit. The vertical axis shows the time of drug intake (24 h
clock; dosing time). Dots represent opening of the electronic
monitor (Medication Event Monitoring System-MEMS R©).
time. Patient 1 (upper panel) executed the dosing regimen
perfectly (taking adherence 100%, correct dosing 100%).
Patient 2 (lower panel) was persistent throughout the
observation period, but showed several irregularities in
the drug intake (taking adherence 94.1%, correct dosing
70.6%). Despite the different execution profile, the ticagrelor-
induced antiplatelet response was only slightly better in
patient 2 (6-months VASP-PRI 28.8% in patient 1, 23.4% in
patient 2).
Limitations of the Study
The baseline imbalance in age and cardiovascular antecedents
(the clopidogrel population was older but had less severe
cardiovascular history) may have introduced a bias, increasing
the between-treatment groups VASP-PRI differences. These
differences reflect the fact that the anti-P2Y12 drug choice was
not randomized, but left to the choice of the cardiologists.
Prasugrel has shown no net superiority with respect to
clopidogrel in very elderly patients (≥75 years) and in those
weighing less than 60 kg due to an increase in bleeding
complications (Wiviott et al., 2007). Ticagrelor has shown a
net benefit when compared to clopidogrel in patients after
acute coronary syndrome. Prasugrel and ticagrelor are now
indicated in patients resistant or poorly responsive to clopidogrel
with prior recurrent cardiovascular events (Wallentin et al.,
2009).
The high adherence observed in this study does not necessarily
reflect the real-life situation. In the trial, all participants were
aware that their adherence was being monitored and had
regular appointments to attend, during which the adherence
results were discussed. This approach has been proven to
enhance successfully adherence to medications (Demonceau
et al., 2013). As adherence was high in all groups, it
cannot be excluded that an effect on platelet inhibition
would have been seen under a specific cutoff level of
adherence.
This study explored only a subset of factors potentially
implicated in the long-term P2Y12 receptor inhibition. Clinical,
demographic, genomic factors not yet identified will probably
emerge in the future and will further clarify these complex
interactions. Procedural heterogeneity in sampling treatment
could have influenced VASP-PRI results, but the risk was
minimized by a strict standardized protocol for drug intake
and blood sampling and by centralizing the analysis in one
laboratory.
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CONCLUSION
Drug adherence to anti-P2Y12 drugs assessed with electronic
monitoring was very high in patients after elective PCI. When
adherence is high, the newer anti-P2Y12 drugs ticagrelor
and prasugrel showed higher antiplatelet inhibition and
less response variability with respect to other anti-P2Y12
drugs.
These data suggest that when adherence to oral anti-
P2Y12 drugs is high, the pharmacokinetic-pharmacodynamic
differences are more important than adherence in determining
platelets’ responsiveness.
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